The Global Influenza Vaccine Market to 2024: Projected to Grow at a CAGR of 6.37% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 7, 2019--The “Influenza Vaccine Market - Forecasts from 2019 to 2024” report has been added to ResearchAndMarkets.com’s offering.
The global influenza vaccine market is projected to grow at a CAGR of 6.37% to reach US$7.547 billion by 2024, from US$5.209 billion in 2018.
Due to the constant changing of circulating influenza viruses, influenza vaccines strains are changed annually (for both the Northern Hemisphere and the Southern Hemisphere) to more closely match currently circulating virus strains (source: WHO).
Hence the rising R&D expenditure and advancements in vaccine technology are driving the growth of the global influenza vaccine market in the forecast period.
Furthermore, growing immunization for the prevention of influenza virus infection will emanate the market growth in the coming years and beyond.
Major industry players profiled as part of the report are Seqirus, GlaxoSmithKline, Sanofi Pasteur, Novavax, Emergent BioSolutions among others.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market.
The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global influenza vaccine value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global influenza vaccine market.
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.6. Base and Forecast Years Timeline
2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
3. Executive Summary
4. Market Dynamics
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry In the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. Global Influenza Vaccine Market by Vaccine Technology
6. Global Influenza Vaccine Market by End-User
7. Global Influenza Vaccine Market by Geography
7.1. North America
7.2. South America
7.3.3. United Kingdom
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.5. Asia Pacific
7.5.3. South Korea
8. Competitive Intelligence
8.1. Competition and Offerings Analysis of Key Vendors
8.2. Recent Investment and Deals
8.3. Strategies of Key Players
9. Company Profiles
9.2. GlaxoSmithKline PLC
9.3. Sanofi Pasteur S.A.
9.4. Novavax Inc.
9.5. Emergent Biosolutions Inc.
9.6. CSL Limited
9.7. Pfizer Limited
9.8. Gamma Vaccines Pty. Ltd.
9.10. F. Hoffmann-La Roche Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/wlxfr9/the_global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190307005677/en/
Laura Wood, Senior Press Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 03/07/2019 01:47 PM/DISC: 03/07/2019 01:47 PM